Omeros (NASDAQ:OMER) Stock

OMEROS CORP

Omeros

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros Corp

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">ANI Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>)</h3>
<ul class="wp-block-list">
<li>On May 22, ANI Pharma launched Phase 4 trial to test Cortrophin Gel dosing for gout flares at Massachusetts General Hospital. &#8220;Gout is a chronic disease that affects millions of patients, including acute flares that can cause extreme pain and temporary disability,&#8221; said Hyon Choi, MD, DrPH, principal investigator of the study and clinical investigator and physician in the Rheumatology Unit at Mass General Research Institute/Massachusetts General Hospital (MGH). &#8220;For some patients, conventional anti-inflammatory treatments do not provide adequate relief from these flares. We look forward to initiating this dose-ranging study, which we believe will provide valuable scientific information about Cortrophin Gel in the treatment of acute gout flares.&#8221; The company's stock fell around 18% over the past month and has a <a href="https://www.benzinga.com/quote/ANIP">52-week low of $52.50</a>.</li>
<li>RSI Value: 29.7</li>
<li>ANIP Price Action: Shares of ANI Pharmaceuticals gained 0.9% to close at $57.79 on Friday.</li>
<li>Edge Stock Ratings: 91.92 Momentum score with Value at 93.51. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="477" height="187" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044146/image-323.png" alt="" class="wp-image-927355" style="width:334px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044146/image-323.png 477w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044146/image-323-300x118.png 300w" sizes="(max-width: 477px) 100vw, 477px" /></figure>
<h3 class="wp-block-heading">Omeros Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>)</h3>
<ul class="wp-block-list">
<li>On May 15, Omeros posted a wider-than-expected quarterly loss. &#8220;We are pleased that our BLA for narsoplimab in TA-TMA has been accepted by FDA, which is a significant milestone for our narsoplimab program and for Omeros,&#8221; said Gregory A. Demopulos, M.D., Omeros&#8217; Chairman and Chief Executive Officer. The company's stock fell around 57% over the past month and <a href="https://www.benzinga.com/quote/OMER">has a 52-week low</a> of $2.97.</li>
<li>RSI Value: 25.3</li>
<li>OMER Price Action: Shares of Omeros fell 1.9% to close at $3.16 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0527">OMER stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0527"><img loading="lazy" decoding="async" width="915" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044237/image-324.png" alt="" class="wp-image-927356" style="width:621px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044237/image-324.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044237/image-324-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044237/image-324-768x711.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<h3 class="wp-block-heading">Agilon Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>)</h3>
<ul class="wp-block-list">
<li>On May 6, the company said total revenue of $1.53 billion fell 4% year-over-year in the first quarter. &#8220;I&#8217;m encouraged by our first quarter results and the progress we are making on key initiatives to drive improved operating performance. With our differentiated Total Care Model, our partnerships remain focused on the entire health of their patients, continuing to deliver significant quality outcomes, and cost-effective care to senior patients,&#8221; said Steven Sell, CEO, agilon health. The company's stock fell around 42% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/AGL">low of $1.50.</a></li>
<li>RSI Value: 29.9</li>
<li>AGL Ltd Price Action: Shares of Agilon Health rose 0.9% to close at $2.22 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0527">AGL shares</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0527"><img loading="lazy" decoding="async" width="883" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044331/image-325.png" alt="" class="wp-image-927358" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044331/image-325.png 883w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044331/image-325-300x289.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26044331/image-325-768x741.png 768w" sizes="(max-width: 883px) 100vw, 883px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Dick&#8217;s Sporting Goods Stock Ahead Of Q1 Earnings</a></li>
</ul>
Photo via Shutterstock

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

ANIP

OMER

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

Needham analyst Serge Belanger reiterates Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) from Hold to Hold.

Reiteration

Analyst Ratings

Needham Reiterates Hold on Omerosto Hold

Earnings

Earnings Misses

Omeros Q1 EPS $(0.58) Misses $(0.57) Estimate

ACOG

AENT

AIRI

AMAT

AREN

BABA

BCLI

BEKE

BFRI

BHST

BIRK

BLIN

BNZI

BRAG

BTBT

BTDR

CAVA

CSIQ

CYCC

DFLI

DOCS

DTIL

DTST

DUOT

EDAP

EDBL

FLNT

FTLF

GAMB

GAME

GLOB

GORV

GOSS

GSX Techedu Inc. American Depositary Shares

GOTU

HAFN

IMCC

INKT

IVVD

JAGX

KORE

KPLT

KULR

LFWD

LGCY

LMFA

LPTH

LTRN

MITQ

MRSN

NICE

NRXP

NTES

NVVE

NXPL

ONDS

ORGN

PAVM

PHGE

PIII

PLBY

POCI

PPSI

PVLA

QUBT

RIME

RNXT

ROLR

SANW

SCWO

SIDU

SNYR

SOBO

SPCE

SRTS

SRXH

SWKH

TIVC

TLSI

TRAK

TSHA

TSSI

Earnings Scheduled For May 15, 2025

Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) will release its quarterly earnings report on Thursday, 2025-05-15. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Omeros to report an earnings per share (EPS) of $-0.60.
Investors in Omeros are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company beat EPS by $0.08, leading to a 3.77% drop in the share price the following trading session.
Here's a look at Omeros's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.71</td>
<td>-0.70</td>
<td>-0.69</td>
<td>-0.58</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.63</td>
<td>-0.64</td>
<td>-0.97</td>
<td>-0.63</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>66.0%</td>
<td>-6.0%</td>
<td>-21.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747231339_0.png" alt="eps graph" />
<h3>Market Performance of Omeros's Stock</h3>
Shares of Omeros were trading at $4.43 as of May 13. Over the last 52-week period, shares are up 27.19%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/OMER/earnings">To track all earnings releases for Omeros visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Examining the Future: Omeros's Earnings Outlook

<h3>Gainers</h3>
<ul>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares increased by 57.2% to $2.94 during Tuesday's after-market session. The market value of their outstanding shares is at $8.9 million. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) stock rose 42.98% to $1.58. The market value of their outstanding shares is at $59.7 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock moved upwards by 40.9% to $1.03. The company's market cap stands at $53.3 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) stock increased by 16.2% to $4.41. The company's market cap stands at $255.5 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares moved upwards by 15.92% to $64.0. The market value of their outstanding shares is at $14.3 billion. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock increased by 15.15% to $1.9. The company's market cap stands at $95.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 95.5% to $0.02 during Tuesday's after-market session. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares fell 44.08% to $0.07. The company's market cap stands at $1.8 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 36.9% to $296.59. The company's market cap stands at $3.8 billion. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock fell 24.91% to $50.0. The market value of their outstanding shares is at $6.1 billion. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) stock declined by 23.96% to $10.41. The market value of their outstanding shares is at $62.2 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) shares decreased by 20.39% to $0.82. The company's market cap stands at $54.6 million. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APYX

ATPC

AXDX

HALO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

KDLY

LUCY

PLRZ

VANI

12 Health Care Stocks Moving In Tuesday's After-Market Session

D. Boral Capital analyst Jason Kolbert maintains Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy and maintains $36 price target.

Price Target

D. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target

<h3>Gainers</h3>
<ul>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares increased by 296.0% to $15.45 during Monday's regular session. The company's market cap stands at $92.3 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock rose 93.34% to $1.79. The market value of their outstanding shares is at $143.7 million. As per the press release, Q1 earnings came out today. </li>
<li>Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) shares increased by 29.55% to $3.77. The market value of their outstanding shares is at $95.4 million. The company's, Q1 earnings came out today. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 25.98% to $461.12. The market value of their outstanding shares is at $6.0 billion. </li>
<li>Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) stock increased by 22.76% to $5.5. The market value of their outstanding shares is at $33.6 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares rose 22.75% to $0.79. The market value of their outstanding shares is at $95.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares declined by 28.8% to $4.4 during Monday's regular session. The company's market cap stands at $254.9 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares declined by 20.0% to $0.12. The company's market cap stands at $2.9 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares fell 15.02% to $0.52. The company's market cap stands at $1.1 million. </li>
<li>Apimeds Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/APUS#AMEX">APUS</a>) shares fell 13.19% to $1.91. The company's market cap stands at $24.2 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock fell 11.18% to $0.14. The company's market cap stands at $4.0 million. </li>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) shares declined by 10.69% to $2.92. The market value of their outstanding shares is at $15.6 million. As per the news, the Q1 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGEN

ALGS

APUS

CTMX

LPCN

WORX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Monday's Intraday Session

Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) ("Omeros" or the "Company") today announced that it has entered into exchange agreements (the "Exchange Agreements") with a limited number of investors who are holders of the Company's 5.25% Convertible Senior Notes due 2026 (the "2026 Convertible Notes") to exchange, on a one-for-one basis, $70.5 million aggregate principal amount of the 2026 Convertible Notes for newly issued 9.50% Convertible Senior Notes due 2029, with a conversion rate set at a 35% premium as described below (the "New Convertible Notes"). The exchange, which extends the maturity of a significant portion of the Company's outstanding indebtedness, is expected to close on or about May 14, 2025.
In addition, Omeros today announced that it has entered into an agreement (the "Note Conversion Agreement") with an investor to convert $10 million aggregate principal amount of 2026 Convertible Notes into shares of the Company's common stock, par value $0.01 per share (the "Equitization Transaction").
Following the completion of these transactions, approximately $17.4 million aggregate principal amount of the 2026 Convertible Notes will remain outstanding. This reduction in principal balance of the 2026 Convertible Notes outstanding will prevent the Company from being required to make a $20.0 million prepayment of the term loan outstanding under its 2024 Credit and Guaranty Agreement. This prepayment otherwise would have become due in November 2025. As a result of these transactions, the Company expects that its outstanding debt will be reduced by $10.0 million and its potential debt repayment obligations over the next 12 months will be reduced from $117.9 million to approximately $17.4 million.

Omeros Agrees To Acquire $80.5M Of Its Convertible Senior Notes Due 2026

Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The resubmission was classified as a Class 2 resubmission and pursuant to the Prescription Drug User Fee Act (PDUFA) has been assigned a target action date for the FDA decision in late September 2025.
The BLA resubmission includes the primary set of analyses comparing overall survival for narsoplimab-treated patients to overall survival for an external control group of TA-TMA patients. Results of those analyses showed clinically meaningful and statistically significant improvements in survival associated with narsoplimab treatment. Also included in the resubmission are data describing survival in Omeros' expanded access program in which adult and pediatric TA-TMA patients were treated with narsoplimab.
Since resubmission of the BLA in late March, Omeros has received and is responding to information requests from FDA and expects an interactive review by FDA.
Omeros is also preparing a marketing authorization application (MAA) for narsoplimab in TA-TMA, which is targeted for submission to the European Medicines Agency later this quarter.

FDA Accepts Omeros' Biologics License Application For Narsoplimab In Transplant-Associated Thrombotic Microangiopathy

U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Monday.
Shares of Eagle Financial Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSI#NASDAQ">EFSI</a>) fell sharply in today's pre-market trading after the company released financial <a href="https://www.benzinga.com/quote/efsi">results for the first quarter</a>.
Eagle Financial Services reported quarterly earnings of 62 cents per share, down from 72 cents per share in the year-ago period.
Eagle Financial Services shares dipped 5.8% to $30.51 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>RXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) shares dipped 10.7% to $12.01 in pre-market trading. Truist Securities analyst Lucas Servera, on April 24, maintained RXO with a Buy and lowered the price target from $24 to $19.</li>
<li>The ODP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODP#NASDAQ">ODP</a>) declined 9.8% to $12.01 in today's pre-market trading. ODP will announce first quarter financial results before the opening bell on Wednesday, May 7.</li>
<li>Hillman Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) shares fell 8.3% to $7.03 in pre-market trading.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) tumbled 6.8% to $6.81 in pre-market trading.</li>
<li>Magnera Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGN#NYSE">MAGN</a>) dipped 6.8% to $13.41 in pre-market trading. Magnera is expected to report second quarter results on May 7.</li>
<li>AleAnna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNA#NASDAQ">ANNA</a>) fell 6.4% to $9.13 in pre-market trading.</li>
<li>Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) fell 2.8% to $13.35 in pre-market trading.</li>
<li>Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) slipped 2.2% to $11.85 in pre-market trading. Delcath Systems will host a conference call on May 8 to discuss results for its first quarter.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 1.5% to $109.34 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a></li>
</ul>
Photo via Shutterstock

ANNA

BLCO

DCTH

EFSI

HLMN

MAGN

NVDA

Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Omeros Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) on Thursday established the Omeros Oncology Clinical Steering Committee to advance Omeros&#8217; OncotoX biologics program focused on <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">acute myeloid leukemia (AML)</a>.
AML is the most fatal form of leukemia. It accounts for approximately 80% of acute leukemias in adults and one-third of all cancers <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44733942/omeros-announces-the-omeros-oncology-clinical-steering-committee-for-aml-to-help-guide-omeros-prop" rel="noreferrer noopener">affecting the blood/bone marrow</a>.
Omeros&#8217; OncotoX program for AML consists of proprietary targeted, engineered molecules (about half the size of an antibody) that deliver a toxic payload within the cancer cells, thereby killing them.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42598739/omeros-antibody-improves-overall-survival-in-rare-complication-after-stem-cell-transplant-stock-surges" rel="noreferrer noopener">Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges</a>
The steering committee will assist Omeros with developing the OncotoX-AML program, designing clinical trials, and interacting with institutional review boards, and it will also participate in OncotoX-AML clinical trials.
In vivo&nbsp;and&nbsp;ex vivo&nbsp;studies have shown that the OncotoX-AML therapeutic is highly effective even at very low doses, providing a significant survival benefit over currently approved combination therapy, like AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Genentech&#8217;s Venclexta (venetoclax) and Bristol Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Vidaza azacitidine).
In studies using primary AML derived from patients, the OncotoX molecule preferentially and efficiently kills AML blasts (abnormal myeloid cells).
OncotoX-AML also targets leukemia stem cells (LSC), often refractory to chemotherapy.
The OncotoX-AML therapeutic is designed specifically to kill both AML blasts and LSCs that can lead to relapse.
Preliminary&nbsp;in vivo&nbsp;tolerability studies demonstrate that the OncotoX therapeutic is well tolerated at doses substantially greater than one order of magnitude above efficacious doses without causing neutropenia or meaningful changes in blood chemistry values.
Omeros is initiating IND-enabling work for its OncotoX-AML therapeutic.
D. Boral analyst Jason Kolbert writes, &#8220;This development is particularly important given the persistent challenges in AML treatment. Despite recent drug approvals, therapeutic options for AML remain limited, especially for patients who are elderly, relapse-prone, or harbor high-risk mutations.&#8221;
Kolbert adds that chemotherapy and existing antibody-drug conjugates often fail to provide durable responses due to narrow therapeutic indices and toxic side effects. By demonstrating high efficacy in preclinical models without significant toxicity, OncotoX-AML presents the potential to address long-standing gaps in AML care.
The analyst maintains a Buy rating on Omeros with <a target="_blank" href="https://www.benzinga.com/quote/OMER/analyst-ratings" rel="noreferrer noopener">a price target of $36</a> while modeling Omeros&#8217; lead therapy, narsoplimab.
In February, the company resubmitted biologics license application for narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Omeros expects the target date for FDA action under the Prescription Drug User Fee Act to be six months following the date of resubmission to the FDA, meaning, in this case, the PDUFA date would be<a href="https://www.benzinga.com/pressreleases/25/03/b44570592/omeros-corporation-reports-fourth-quarter-and-year-end-2024-financial-results" target="_blank" rel="noreferrer noopener"> September 2025</a>.
The company expects to submit our European marketing authorization application for narsoplimab in TA-TMA in the first half of 2025.&nbsp;
Price Action: OMER stock is up 13.2% at $6.64 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44770461/intel-on-slump-as-china-hits-us-made-chips-with-tariffs-amd-and-taiwan-semiconductor-rise-on-exemption-boost" target="_blank" rel="noreferrer noopener">China Hits US-Made Chips With Tariffs, But Those Outsourcing To Taiwan Semiconductor Exempt</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Analyst Color

Biotech

Health Care

General

ABBV

RHHBY

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

– The Steering Committee brings together distinguished clinical experts in AML from leading National Comprehensive Cancer Network Centers –
Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros' OncotoX biologics program focused on acute myeloid leukemia (AML). AML is the most fatal form of leukemia and accounts for approximately 80 percent of acute leukemias in adults and one-third of all cancers affecting the blood/bone marrow, representing a high unmet need. Omeros' OncotoX program for AML consists of proprietary targeted, engineered molecules (about half the size of an antibody) that deliver a toxic payload within the cancer cells, thereby killing them.

Omeros Establishes Oncology Clinical Steering Committee Of Leading AML Experts From Top Cancer Centers To Advance Its OncotoX Biologics Program Targeting High-Unmet-Need Acute Myeloid Leukemia With Proprietary Engineered Molecules Designed To Deliver Cancer-Killing Payloads

Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.82) by 23.17 percent. This is unchanged from the same period last year.

Earnings Beats

Omeros Q4 2024 GAAP EPS $(0.63) Beats $(0.82) Estimate

<h3>Companies Reporting Before The Bell</h3>
• Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) is estimated to report quarterly loss at $1.36 per share on revenue of $2.69 million. 
• ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) is likely to report quarterly loss at $0.24 per share on revenue of $3.77 million. 
• Synergy CHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNYR#NASDAQ">SNYR</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $10.55 million. 
• Westport Fuel Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WPRT#NASDAQ">WPRT</a>) is estimated to report quarterly loss at $0.28 per share on revenue of $70.35 million. 
• Loar Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $102.51 million. 
• Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) is expected to report earnings for its fourth quarter. 
• Edible Garden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) is estimated to report quarterly loss at $9.00 per share on revenue of $4.12 million. 
• Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $16.98 million. 
• Lazydays Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) is expected to report earnings for its fourth quarter. 
• FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) is projected to report quarterly loss at $0.84 per share on revenue of $11.61 million. 
• Sigma Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGML#NASDAQ">SGML</a>) is projected to report quarterly earnings at $0.06 per share on revenue of $77.16 million. 
• Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) is expected to report quarterly loss at $4.38 per share on revenue of $3.06 million. 
• LM Funding America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMFA#NASDAQ">LMFA</a>) is estimated to report quarterly loss at $1.67 per share on revenue of $1.50 million. 
• Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $6.20 million. 
• BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $7.72 million. 
• IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) is estimated to report quarterly loss at $0.39 per share on revenue of $10.43 million. 
• LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) is expected to report quarterly loss at $0.14 per share on revenue of $23.55 million. 
• Palvella Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) is likely to report earnings for its fourth quarter. 
• Nano X Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>) is expected to report quarterly loss at $0.15 per share on revenue of $3.80 million. 
• Chicago Atlantic BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIEN#NASDAQ">LIEN</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $11.00 million. 
• BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) is likely to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• T Stamp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) is projected to report quarterly loss at $1.80 per share on revenue of $510 thousand. 
• Local Bounti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOCL#NYSE">LOCL</a>) is expected to report quarterly loss at $3.89 per share on revenue of $10.95 million. 
• Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) is estimated to report quarterly loss at $0.43 per share on revenue of $3.89 million. 
• Siyata Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) is projected to report earnings for its fourth quarter. 
• Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $24.03 million. 
• Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $81.13 million. 
• Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) is expected to report earnings for its fourth quarter. 
• CXApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $2.00 million. 
• Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) is projected to report earnings for its fourth quarter. 
• Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) is projected to report earnings for its Fiscal Year 2024. 
• Spruce Power Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) is expected to report earnings for its fourth quarter. 
• Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) is estimated to report earnings for its fourth quarter. 
• Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $92.50 million. 
• Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) is estimated to report quarterly loss at $0.16 per share on revenue of $3.90 million. 
• Red Cat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) is projected to report quarterly loss at $0.09 per share on revenue of $7.49 million. 
• Digi Power X (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGXX#NASDAQ">DGXX</a>) is likely to report quarterly loss at $0.12 per share on revenue of $14.30 million. 
• Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) is projected to report earnings for its fourth quarter. 
• Nortech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) is likely to report earnings for its fourth quarter. 
• VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) is projected to report quarterly loss at $0.05 per share on revenue of $545 thousand. 
• iShares Gold Trust Shares of the iShares Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAU#NYSE">IAU</a>) is projected to report quarterly loss at $0.02 per share on revenue of $37.70 million. 
• i-80 Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IAUX#AMEX">IAUX</a>) is projected to report earnings for its fourth quarter. 
• Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) is expected to report earnings for its fourth quarter. 
• Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) is likely to report earnings for its fourth quarter. 
• MDB Capital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDBH#NASDAQ">MDBH</a>) is estimated to report earnings for its fourth quarter. 
• Duos Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOT#NASDAQ">DUOT</a>) is expected to report quarterly loss at $0.34 per share on revenue of $1.60 million. 
• Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) is likely to report quarterly loss at $0.63 per share on revenue of $1.00 million. 
• Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) is projected to report earnings for its fourth quarter. 
• CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) is likely to report quarterly loss at $0.07 per share on revenue of $9.43 million. 
• Venu Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VENU#AMEX">VENU</a>) is expected to report earnings for its fourth quarter. 
• Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) is estimated to report earnings for its fourth quarter. 
• ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) is projected to report quarterly loss at $1.33 per share on revenue of $6.30 million. 
• Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) is estimated to report earnings for its fourth quarter. 
• Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) is projected to report earnings for its fourth quarter. 
• Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) is projected to report quarterly loss at $0.96 per share on revenue of $1.70 million. 
• CaliberCos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWD#NASDAQ">CWD</a>) is likely to report quarterly loss at $0.04 per share on revenue of $6.69 million. 
• Precipio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) is expected to report earnings for its fourth quarter. 
• Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) is projected to report quarterly earnings at $1.39 per share on revenue of $234.69 million. 
• PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) is likely to report quarterly earnings at $3.24 per share on revenue of $2.34 billion. 
• Invesco National AMT-Free Municipal Bond ETFo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PZA#NYSE">PZA</a>) is projected to report quarterly earnings at $0.25 per share on revenue of $168.10 million. 
• BioHarvest Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHST#NASDAQ">BHST</a>) is likely to report earnings for its fourth quarter. 
• Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) is projected to report quarterly loss at $0.01 per share on revenue of $212.30 million. 
• Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) is expected to report quarterly loss at $8.40 per share on revenue of $6.30 million. 
• Innovate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VATE#NYSE">VATE</a>) is likely to report earnings for its fourth quarter. 
• TechTarget (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTGT#NASDAQ">TTGT</a>) is expected to report quarterly earnings at $0.45 per share on revenue of $62.37 million. 
• Rekor Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REKR#NASDAQ">REKR</a>) is expected to report quarterly loss at $0.08 per share on revenue of $12.91 million. 
• Flexible Solutions Intl (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSI#AMEX">FSI</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $10.83 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Omeros

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL